Effects of polymorphism of the β1 adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol

Abstract

Metoprolol is a lipophilic β1 selective adrenergic receptor antagonist used in antihupertensive therapy. It is metabolized by the protien product of the cytochrome P450 2D6 (CYP2D6) gene. Few studies have been performed on the association between the β 1 adrenoreceptor, CYP2D6 polymorphism and blood pressure. The one reported here is a prospetive, observational, clinical study in Chinese Hon hypertensive patients on the combined influences of CYP2D6 and β1 adrenoreceptor polymorphisms on the therapeutic effects of metoprolol in 300 out-patients with essential hypertension. The same dose of metoprolol achieved different therapeutic effects in patients with different CYP2D6 abd β1 adrenoreceptor polymorphisms. Additionally, different doses of metoprolol could achieve the same therapeutic effects in patients with different CYP2D6 and β1 adrenoreceptor polymorphisms. Knowledge of the combination of CYP2D6 and β1 adrenoreceptor polymorphisms may be used to guide antihypertensive therapy using β1 adrenoreceptor antagonists. Copyright © 2008 Field House Publishing LLP.